Pregnancy-associated venous thromboembolic disease: Prediction, prevention, and therapy;Venöse thrombose in der schwangerschaft: Prädiktion, prävention und therapie

Hamostaseologie

Volumn 26, Issue 1, 2006, Pages 63-71

  Zotz, Rainer B ^a   Gerhardt, A ^a   Scharf, R E ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Pregnancy; Prevention; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; PROTHROMBIN;

DISEASE ASSOCIATION; FAMILY HISTORY; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INJURY; MATERNAL MORTALITY; MUTATION; PREGNANCY; PROPHYLAXIS; PUERPERIUM; REVIEW; RISK FACTOR; SURGICAL RISK; THROMBOEMBOLISM; VEIN THROMBOSIS; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; FEMALE; GENETICS; IMMUNOLOGY; MORTALITY; PREGNANCY COMPLICATION;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTHROMBIN; THROMBOEMBOLISM;

EID: 33645235860     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616881     Document Type: Review

References (74)

1. National Institute of Health Consensus Development Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256: 744-9.
2. Kierkegaard A. Incidence and diagnosis of deep-vein thrombosis associated with pregnancy. Acta Obs Gynecol Scand 1983; 62: 239-43.
3. Treffers PE, Huidekoper BL, Weenink GH et al. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynecol Obs 1983; 21: 327-31.
4. Bergqvist A, Bergqvist D, Hallbook T. Deep-vein thrombosis during pregnancy - a prospective-study. Acta Obs Gynecol Scand 1983; 62: 443-8.
5. Mccoll MD, Ramsay JE, Tait RC et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-8.
6. The National Institute for Clinical Excellence Scottish Executive Health Department and Department of Health Social Services and Public Safety: Northern Ireland. Confidential enquiries into maternal deaths in the United Kingdom 1997-99. London: TSO 2001.
7. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: The Scottish experience. Scot Med J 1996; 41: 83-6.
8. Greer IA. Haemostasis and thrombosis in pregnancy. In: Bloom AL, Forbes CD, Thomas DP et al. (eds). Haemostasis and thrombosis. London: Churchill Livingstone 1994: 987-1015.
9. Ware JA, Coller BS. Platelet morphology, biochemistry, and function. In: Beutler E, Lichtmann MA, Coller BS et al. (eds). Hematology. New York: McGraw-Hill 1995: 1161-201.
10. Greer IA. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology. Baill Clin Obs Gynaecol 1997; 11: 403-30.
11. Clark P, Brennand J, Conkie JA et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-70.
12. Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obs Gynaecol 1997; 104: 191-7.
13. Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000 10; 342: 374-80.
14. Bergqvist D, Hedner U. Pregnancy and venous thromboembolism. Acta Obs Gynecol Scand 1983; 62: 449-53.
15. Cockett FB, Thomas ML, Negus D. Iliac vein compression - its relation to iliofemoral thrombosis and post-thrombotic syndrome. Br Med J 1967; 2: 214-9.
16. Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000; 342: 424-5.
17. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood-coagulation factor-V associated with resistance to activated protein-C. Nature 1994; 369: 64-7.
18. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
19. Virchow R. Phlogose und Thrombose im Gefäßsystem. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin 1856.
20. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1453-7.
21. Conard J, Horellou MH, Vandreden P et al. Thrombosis and pregnancy in congenital deficiencies in AT-III, protein-C or protein-S - study of 78 women. Thromb Haemost 1990; 63: 319-20.
22. DeStefano V, Leone G, Mastrangelo S et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin-III, protein-C, protein-S. Thromb Haemost 1994; 71:799-800.
23. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency - A cooperative, retrospective study. Arteriosclerosis Thromb Vasc Biol 1996; 16: 742-8.
24. Friederich PW, Sanson BJ, Simioni P et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis. Ann Intern Med 1996; 125: 955-60.
25. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77-85.
26. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein-C - prediction of a cofactor to activated protein-C. Proc Nat Acad Sci USA 1993; 90: 1004-8.
27. Koster T, Rosendaal FR, Briet E et al. Protein-C deficiency in a controlled series of unselected outpatients - an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-61.
28. Van den Belt AGM, Prins MH, Huisman MV et al. Familial thrombophilia: A review analysis. Clin Appl Thromb Hemost 1996; 2: 227-36.
29. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein-C as a basis for venous thromboembolism associated with pregnancy and oral-contraceptives. Am J Obs Gynecol 1995: 173: 210-3.
30. Hallak M, Senderowicz J, Cassel A et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obs Gynecol 1997; 176: 889-93.
31. Bokarewa MI, Bremme K, Blomback M. Arg(506)-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-8.
32. Grandone E, Margaglione M, Colaizzo D et al. Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obs Gynecol 1998; 179: 1324-8.
33. Mccoll MD, Ellison J, Reid F et al. Prothrombin 20210 G -> A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obs Gynaecol 2000; 107: 565-9.
34. Martinelli I, De Stefano V, Taioli E et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87: 791-5.
35. Rosendaal FR, Koster T, Vandenbroucke JP et al. High-risk of thrombosis in patients homozygous for factor-V Leiden (activated protein-C resistance). Blood 1995; 85: 1504-8.
36. Emmerich J, Rosendaal FR, Cattaneo M et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Thromb Haemost 2001; 86: 809-16.
37. Pabinger I, Nemes L, Rintelen C et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000; 1: 37-41.
38. Middeldorp S, Libourel EJ, Hamulyak K et al. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001; 113: 553-5.
39. Smirnov MD, Safa O, Esmon NL et al. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 1999; 94: 3839-46.
40. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood 1999; 94: 2169-78.
41. Rosendaal FR, Doggen CJM, Zivelin A et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-8.
42. Seligsohn U, Lubetsky A. Medical progress: Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
43. Ginsberg JS, Wells PS, BrillEdwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
44. Mateo J, Oliver A, Borrell M et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism - Results of the Spanish multicentric study on thrombophilia (EMET-study). Thromb Haemost 1997; 77: 444-51.
45. Khamashta MA, Cuadrado MJ, Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
46. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome - Report of an international workshop. Arth Rheum 1999; 42: 1309-11.
47. Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus 1998; 7: S52-4.
48. Gharavi AE, Sammaritano LR, Wen JY et al. Characteristics of human-immunodeficiency-virus and chlorpromazine-induced antiphospholipid antibodies - effect of beta(2), glycoprotein-I on binding to phospholipid. J Rheum 1994; 21: 94-9.
49. Love PE, Santoro SA. Antiphospholipid antibodies - anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (Sle) and in non-Sle disorders - prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
50. Long AA, Ginsberg JS, BrillEdwards P et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus - A cross-sectional study. Thromb Haemost 1991; 66: 520-4.
51. Ginsberg JS, BrillEdwards P, Johnston M et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus - A cross-sectional study. Blood 1992; 80: 975-80.
52. Simioni P, Prandoni P, Zanon E et al. Deep venous thrombosis and lupus anticoagulant-A case-control study. Thromb Haemost 1996; 76: 187-9.
53. Zotz RB, Gerhardt A, Scharf RE. Prediction, prevention, and treatment of venous thromboembolic disease in pregnancy. Sem Thromb Hemost 2003; 29: 143-53.
54. Zotz RB, Gerhardt A, Scharf RE. Inherited thrombophilia and gestational venous thromboembolism. Best Pract Clin Haematol 2003; 16: 243-59.
55. Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343: 1439-44.
56. Pabinger I, Grafenhofer H, Kaider A et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3: 949-54.
57. Zotz RB, Gerhardt A, Scharf RE. Venöse Thrombose in der Schwangerschaft. Hämostaseologie 2006; 26: 63-71.
58. Pabinger I, Grafenhofer H, Kyrle PA et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100: 1060-2.
59. Bates SA, Greer IA, Hirsh J et al. Use of antithrombotic agents during pregnancy. Chest 2004; 126: 627S-44S.
60. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353(9160): 1258-65.
61. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348(9032): 913-6.
62. Rushton ID. Placental pathology in spontaneous miscarriage. In: Beard RWSF (ed. Early pregnancy loss: mechanisms and treatment. London: RCOG 1988: 149-58.
63. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
64. Sanson BJ, Lensing AWA, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: A systematic review. Thromb Haemost 1999; 81: 668-72.
65. Douketis JD, Ginsberg JS, Burrows RF et al. The effects of long-term heparin therapy during pregnancy on bone density - A prospective matched cohort study. Thromb Haemost 1996; 75: 254-7.
66. Pettila V, Kaaja R, Leinonen P et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999; 96: 275-82.
67. Elkayam U. Pregnancy through a prosthetic heart valve. J Am Coll Cardiol 1999; 33: 1642-5.
68. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves -A systematic review of the literature. Arch Intern Med 2000; 160: 191-6.
69. Guyatt G, Schunemann HJ, Cook D et al. Applying the grades of recommendation for antithrombotic and thrombolytic therapy - The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 179S-87S.
70. Gerhardt A, Zotz RB, Struve S et al. Homozygous and combined heterozygous factor V G1691A and prothrombin G20210A mutations as predictors of venous thrombosis during pregnancy. Thromb Haemost 2001 (Suppl): A 2982.
71. Lindqvist PG, Svensson PJ, Marsal K et al. Activated protein C resistance (FV : Q(506)) and pregnancy. Thromb Haemost 1999; 81: 532-7.
72. Martinelli I, Legnani C, Bucciarelli P et al. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86: 800-3.
73. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-31S.
74. Mccoll MD, Walker ID, Greer IA. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br J Obs Gynaecol 1999; 106: 756-66.